Browse the corpus
Walk the Even Hospital Database by book and chapter — the raw source passages that ground Ask, DDx, and the rest.
1 passage
REFERENCES Alberts DS, Jiang C, Liu PY, et al, “Long-Term Follow-Up of a Phase II Trial of Oral Altretamine for Consolidation of Clinical Complete Remission in Women With Stage III Epithelial Ovarian cancer in the Southwest Oncology Group,” Int J Gynecol Cancer, 2004, 14(2):224-8. Damia G and D'Incalci M, “Clinical Pharmacokinetics of Altretamine,” Clin Pharmacokinet , 1995, 28(6):439-48. [PubMed 7656502 ] Keldsen N, Havsteen H, Vergote I, et al, “Altretamine (Hexamethylmelamine) in the Treatment of Platinum-Resistant Ovarian Cancer: A Phase II Study,” Gynecol Oncol , 2003, 88(2):118-22. [PubMed 12586589 ] Markman M, Blessing JA, Moore D, et al, “Altretamine (Hexamethylmelamine) in Platinum-Resistant and Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Phase II Trial,” Gynecol Oncol , 1998, 69(3):226-9. [PubMed 9648592 ] National Institute for Occupational Safety and Health (NIOSH), "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012." Available at file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf . Accessed January 21, 2013. Topic 8486 Version 43.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [1104-58.240.65.66-4367187BB2-S244013.14]